Report #2840782

Received May 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TN
Recovered: Unknown
Vaccinated: Feb 1, 2025
Onset: Feb 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

first dose of Shingrix on 18Dec2023 and the second dose in February 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 81-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (a patient received the first dose of Shingrix on 18-Dec-2023). In FEB-2025, the patient received the 2nd dose of Shingrix. In FEB-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: first dose of Shingrix on 18Dec2023 and the second dose in February 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 05-MAY-2025 Pharmacist reported that a patient received the first dose of Shingrix on 18 December 2023 and the second dose in February of 2025 which led to drug dose administration interval too long. Consented to follow up.